SG11201700481YA - Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof - Google Patents

Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof

Info

Publication number
SG11201700481YA
SG11201700481YA SG11201700481YA SG11201700481YA SG11201700481YA SG 11201700481Y A SG11201700481Y A SG 11201700481YA SG 11201700481Y A SG11201700481Y A SG 11201700481YA SG 11201700481Y A SG11201700481Y A SG 11201700481YA SG 11201700481Y A SG11201700481Y A SG 11201700481YA
Authority
SG
Singapore
Prior art keywords
salts
ursodeoxycholic
combinations
preparation
methods
Prior art date
Application number
SG11201700481YA
Other languages
English (en)
Inventor
Liping Liu
Original Assignee
Shenzhen Hightide Biopharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Hightide Biopharmaceutical Ltd filed Critical Shenzhen Hightide Biopharmaceutical Ltd
Publication of SG11201700481YA publication Critical patent/SG11201700481YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
SG11201700481YA 2014-07-29 2015-07-28 Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof SG11201700481YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462030140P 2014-07-29 2014-07-29
US201462030147P 2014-07-29 2014-07-29
US201562128077P 2015-03-04 2015-03-04
PCT/CN2015/085350 WO2016015634A1 (en) 2014-07-29 2015-07-28 Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof

Publications (1)

Publication Number Publication Date
SG11201700481YA true SG11201700481YA (en) 2017-02-27

Family

ID=55216773

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201700481YA SG11201700481YA (en) 2014-07-29 2015-07-28 Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof

Country Status (16)

Country Link
US (4) US10301303B2 (enExample)
EP (1) EP3174874B1 (enExample)
JP (4) JP6917144B2 (enExample)
KR (3) KR20250008786A (enExample)
CN (2) CN106687460B (enExample)
AU (2) AU2015296098B2 (enExample)
BR (1) BR112017001623B1 (enExample)
CA (3) CA3194562C (enExample)
DK (1) DK3174874T3 (enExample)
EA (1) EA032971B1 (enExample)
ES (1) ES2835874T3 (enExample)
IL (3) IL294063B2 (enExample)
MX (3) MX373840B (enExample)
NZ (1) NZ728488A (enExample)
SG (1) SG11201700481YA (enExample)
WO (1) WO2016015634A1 (enExample)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
JP6716468B2 (ja) * 2014-05-05 2020-07-01 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 肥満、糖尿病、または癌を治療するためのウルソル酸および／またはレスベラトロールを含む方法および組成物
WO2015183794A1 (en) * 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
EP3712254A1 (en) 2014-05-28 2020-09-23 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
CA3194562C (en) * 2014-07-29 2026-03-17 Shenzhen Hightide Biopharmaceutical, Ltd. Berberine-ursodeoxycholic salt, method of preparation and application therof
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
WO2016161921A1 (en) * 2015-04-06 2016-10-13 Shenzhen Hightide Biopharmaceutical, Ltd. Conjugate compounds of ursodeoxycholic, berberine or l-carnitine, and compositions and methods thereof
US12137716B2 (en) 2015-04-16 2024-11-12 Michael Hudnall Methods of liver disease treatment
CN105168228B (zh) * 2015-11-04 2016-06-22 北京凯因科技股份有限公司 奥贝胆酸和小檗碱的复方组合物及其应用
CN116492339A (zh) 2015-11-13 2023-07-28 深圳君圣泰生物技术有限公司 一种组合物及其用途、药物制剂
CN105693805A (zh) * 2016-03-15 2016-06-22 合肥华方医药科技有限公司 一种胆酸类小檗碱偶合物的制备及医药用途
CN105801663A (zh) * 2016-03-15 2016-07-27 合肥华方医药科技有限公司 一种熊果酸小檗碱偶合物的制备方法及医药用途
GB201605013D0 (en) * 2016-03-24 2016-05-11 Inst Of Food Res S-methylcysteine sulfoxide for prostate cancer treatment
ITUA20163025A1 (it) 2016-04-29 2017-10-29 Sochim Int S P A Composizione per il trattamento della sindrome dell’ovaio policistico
EP4177335A1 (en) 2016-05-05 2023-05-10 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
EP3456328A4 (en) * 2016-05-10 2020-02-26 Shenzhen Hightide Biopharmaceutical., Ltd. COMPOSITION AND USE AND PHARMACEUTICAL PREPARATION THEREOF
WO2017218004A1 (en) * 2016-06-17 2017-12-21 Michael Hudnall Medical food for patients with chronic liver disease
CN105963306B (zh) * 2016-07-05 2018-08-17 福州大学 一种具有协同抗肿瘤转移活性的药物组合物
US10702567B2 (en) 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
ES2874187T3 (es) * 2016-09-14 2021-11-04 Phoenix Biotechnology Inc Método y composiciones para el tratamiento de una infección viral
US10729735B1 (en) 2016-09-14 2020-08-04 Phoenix Biotechnology, Inc. Method and compostitions for treating coronavirus infection
US10703761B2 (en) * 2016-10-18 2020-07-07 City Of Hope Bile acid receptor modulators and methods of use thereof
SG11201903697WA (en) 2016-11-04 2019-05-30 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
EP3548507A4 (en) 2016-12-05 2020-07-15 Children's Hospital Medical Center COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
US10471007B2 (en) * 2016-12-16 2019-11-12 Jeffrey R Olynyk Sublingual therapeutic solutions and methods
IT201700032960A1 (it) * 2017-03-24 2018-09-24 Akademy Pharma S R L Composto nutraceutico per il trattamento dell’eccesso di peso e della moderata ipercolesterolemia e disglicemia
BR112019020225A2 (pt) * 2017-03-28 2020-04-22 IRP Health Pty Ltd alcaloides berberina na prevenção e/ou tratamento de doença intestinal
EP3609997A4 (en) 2017-04-14 2021-03-03 Children's Hospital Medical Center COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES
WO2018200736A2 (en) * 2017-04-25 2018-11-01 The Buck Institute For Research On Aging Formulations for extending lifespan and healthspan
CN108864077B (zh) 2017-05-12 2020-05-22 深圳君圣泰生物技术有限公司 小檗碱有机酸盐的固体形式及其制备方法
EP3658139A4 (en) * 2017-07-25 2021-04-07 Cedars-Sinai Medical Center METHOD OF TREATMENT OF HEPER DISEASES
US11865106B2 (en) * 2017-08-11 2024-01-09 Shenzhen Hightide Biopharmaceutical, Ltd. Methods and compositions for treatment of inflammatory bowel disease
US12297457B2 (en) 2017-10-10 2025-05-13 Children's Hospital Medical Center Esophageal tissue and/or organoid compositions and methods of making same
JP2021504541A (ja) * 2017-11-29 2021-02-15 ビーエイエスエフ・ソシエタス・エウロパエアＢａｓｆ Ｓｅ 保存安定性酵素調製物、それらの製造およびそれらを使用する方法
EP3727394A4 (en) 2017-12-21 2021-09-08 Children's Hospital Medical Center DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
US12171748B2 (en) 2018-05-29 2024-12-24 IRP Health Pty Ltd Nitroimidazole formulations
US12421500B2 (en) 2018-07-26 2025-09-23 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
JP2021535753A (ja) 2018-09-12 2021-12-23 チルドレンズ ホスピタル メディカル センター 造血幹細胞およびその派生体の生成のためのオルガノイド組成物
US11802103B2 (en) 2018-09-25 2023-10-31 Ponce De Leon Health Designated Activity Company Process of making calcium alpha-ketoglutarate
CN109303921B (zh) * 2018-10-30 2021-02-09 中国药科大学 Fxr激动剂与sirt1激动剂联用在制备抗肝纤维化药物中的应用
IT201800011155A1 (it) * 2018-12-17 2020-06-17 S&R Farm S P A uso di una miscela di berberina e resveratrolo per il controllo delle dislipidemie
CN111499626A (zh) * 2019-01-31 2020-08-07 西南大学 一种表小檗碱的合成方法及应用
WO2020160371A1 (en) 2019-02-01 2020-08-06 The University Of Hong Kong Innervated organoid compositions and methods of making same
CN109999034A (zh) * 2019-02-11 2019-07-12 浙江理工大学 肿瘤蛋白tnik激酶靶向天然小分子抑制剂及其应用
WO2020179747A1 (ja) * 2019-03-01 2020-09-10 学校法人慶應義塾 Ｈｉｆ抑制用組成物
CN109806264B (zh) * 2019-04-10 2021-04-02 江苏海钥医药科技有限公司 药物组合物及其应用
CA3141814A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
CN114174494A (zh) 2019-05-31 2022-03-11 儿童医院医学中心 产生和扩增造血干细胞的方法
CN112076199A (zh) * 2019-06-13 2020-12-15 谢亚坚 一种降血糖降血脂和降血胆固醇方剂
CN110368392A (zh) * 2019-08-20 2019-10-25 延边大学 科罗索酸在制备抗肝损伤药物或抗肝损伤保健品中的应用
CN112851660B (zh) * 2019-11-12 2022-03-18 广东药科大学 含有小檗碱的酸-碱加成盐、其制备方法及其作为药物的用途
CN111116578B (zh) * 2019-12-26 2021-06-04 深圳市老年医学研究所 去亚甲基小檗碱的制备方法及其应用
KR102150821B1 (ko) * 2020-01-22 2020-09-03 주식회사 에이스바이오메드 간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection
WO2021232071A1 (en) * 2020-05-15 2021-11-18 Van Nguyen Anh Solid lipid nano-composition containing berberine and cinnamonaldehyde effective in treating diabetes, dyslipidemia, and method of preparing the same
WO2021247293A1 (en) * 2020-06-02 2021-12-09 Glykon Technologies Group, Llc Methods and pharmaceutical preparations for elevating ketone utilization
US12624013B2 (en) * 2020-08-12 2026-05-12 Archer- Daniels-Midland Company Purification of 2,5-furandicarboxylic acid, dimethyl ester and other esterified products
KR102636847B1 (ko) * 2020-09-18 2024-02-19 경북대학교 산학협력단 티아민 유도체를 포함하는 이식편대숙주질환 예방 또는 치료용 약학적 조성물
CN114195850B (zh) * 2020-09-18 2024-08-16 成都贝诺科成生物科技有限公司 一种用于防治肝病的化合物及其制药用途
CN116782898A (zh) * 2020-10-23 2023-09-19 深圳君圣泰生物技术有限公司 小檗碱熊去氧胆酸盐的组合物及其用于治疗脂肪性肝病、糖尿病和高脂血症的方法
WO2022161468A1 (en) * 2021-01-28 2022-08-04 Shenzhen Hightide Biopharmaceutical Ltd. Compositions of berberine ursodeoxycholate and methods thereof for treating primary sclerosing cholangitis
CN113143962B (zh) * 2021-05-11 2022-08-05 四川九章生物科技有限公司 一种治疗高脂血症的药物组合物及其制备方法
IL310559A (en) * 2021-08-23 2024-03-01 Paxmedica Inc Methods for treating disorders of the nervous system with antipurinergic substances
CN113577064B (zh) * 2021-09-09 2023-07-04 浙江中医药大学 一种增强肿瘤免疫的联合用药物组合物及其应用
TW202333660A (zh) * 2021-11-01 2023-09-01 日商小林製藥股份有限公司 軟骨再生促進劑
WO2023091173A1 (en) * 2021-11-16 2023-05-25 Michael Hudnall Methods of liver disease treatment
WO2023088463A1 (en) * 2021-11-22 2023-05-25 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods of berberine ursodeoxycholate for modulating gut microbiome compositions
CN116178384A (zh) * 2021-11-29 2023-05-30 湖南师范大学 四种小檗碱中短链脂肪酸盐的制备
CN114716498B (zh) * 2022-01-20 2024-01-23 成都贝诺科成生物科技有限公司 一种高稳定性的失碳熊去氧胆酸小檗碱盐晶型及其制备方法
KR102951283B1 (ko) * 2022-05-06 2026-04-20 주식회사 알트메디칼 이소퀴놀린 유도체 화합물을 이용한 시험관 내 미토파지 활성 촉진방법
US20250375459A1 (en) * 2022-07-01 2025-12-11 Intercept Pharmaceuticals, Inc. Methods for ameliorating cognitive impairment using bile acid derivatives
CN115011661B (zh) * 2022-07-22 2024-06-21 湖南科瑞生物制药股份有限公司 一种3β-熊去氧胆酸的合成方法
KR102828609B1 (ko) * 2022-10-11 2025-07-02 주식회사 알트메디칼 이소퀴놀린 유도체를 유효성분으로 포함하는 파킨슨병의 예방 또는 치료용 조성물
KR102939710B1 (ko) * 2022-10-14 2026-03-16 주식회사 알트메디칼 이소퀴놀린 유도체를 유효성분으로 포함하는 말초신경병증의 예방 또는 치료용 조성물
KR20240054685A (ko) * 2022-10-19 2024-04-26 주식회사 알트메디칼 이소퀴놀린 유도체를 유효성분으로 포함하는 멜라스증후군의 예방 또는 치료용 조성물
KR102918818B1 (ko) * 2022-11-10 2026-01-27 국립강릉원주대학교산학협력단 자작나무 잎 추출물을 포함하는 근력강화용 조성물
WO2024120452A1 (en) * 2022-12-07 2024-06-13 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods for prophylaxis and treatment of covid-19
EP4642454A1 (en) * 2022-12-30 2025-11-05 Shenzhen Hightide Biopharmaceutical Ltd. Pharmaceutical combinations and compositions, and methods of use thereof
AU2024222862A1 (en) * 2023-02-15 2025-09-11 Shenzhen Hightide Biopharmaceutical Ltd. Berberine tauroursodeoxycholate compositions and methods thereof
WO2024179570A1 (en) * 2023-03-01 2024-09-06 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods for treating severe hypertriglyceridemia
WO2024222408A1 (zh) * 2023-04-28 2024-10-31 杭州居维叶生物医药有限公司 一种黄连素维生素c盐组合物、制备方法及其应用
WO2024245371A1 (zh) * 2023-05-31 2024-12-05 上海复宏汉霖生物技术股份有限公司 一种组合产品、盐及其用于治疗神经退行性疾病或病症的用途
WO2024245370A1 (zh) * 2023-05-31 2024-12-05 上海复宏汉霖生物技术股份有限公司 一种组合产品、盐及其用途
CN116850186A (zh) * 2023-06-02 2023-10-10 深圳市第二人民医院(深圳市转化医学研究院) 一种多靶点神经元保护剂在防治神经系统退行性疾病中的应用
CN121794267A (zh) * 2023-09-07 2026-04-03 迈拓基因株式会社 小檗红碱相关化合物
CN117731674A (zh) * 2023-12-14 2024-03-22 成都贝诺科成生物科技有限公司 失碳熊去氧胆酸小檗碱盐在制备预防和/或治疗消化道炎症的药物中的用途
WO2025130826A1 (en) * 2023-12-18 2025-06-26 Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences Compositions and methods for treating cancer
KR20250116419A (ko) * 2024-01-25 2025-08-01 주식회사 알트메디칼 이소퀴놀린 유도체 화합물을 유효성분으로 포함하는 당뇨병성 신증의 예방 또는 치료용 약학적 조성물
CN120267634B (zh) * 2025-04-09 2026-01-27 中国药科大学 一种外泌体融合肝靶向脂质体递药系统及其制备方法和应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5529075B2 (enExample) * 1971-08-20 1980-07-31
IT1136624B (it) * 1981-05-21 1986-09-03 Erregierre Ind Chim Spa Prodotti di salificazione di acidi colici,processo per la loro preparazione e composizioni terapeutiche che li comprendono come principio attivo
JPS60163897A (ja) * 1984-02-06 1985-08-26 Tokyo Tanabe Co Ltd ウルソデオキシコ−ル酸メグルミン塩およびその注射剤
JPS6256192A (ja) 1985-09-06 1987-03-11 Hitachi Ltd 感熱転写材
IT1245889B (it) * 1991-04-12 1994-10-25 Alfa Wassermann Spa Formulazioni farmaceutiche per uso orale gastroresistenti contenenti sali di acidi biliari.
JPH06256192A (ja) 1993-03-05 1994-09-13 Nitsusui Seiyaku Kk 液状薬剤の製造法
FR2796551B1 (fr) * 1999-07-23 2003-07-25 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
KR20050081477A (ko) * 2004-02-13 2005-08-19 켐젠주식회사 암로디핀 담즙산염, 그의 제조방법 및 이를 함유하는경구투여용 약학 조성물
CN1759834B (zh) 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
CN1762367A (zh) 2004-10-18 2006-04-26 孙民富 熊去氧胆酸滴丸的处方及其制作方法
WO2007005643A2 (en) 2005-07-01 2007-01-11 Concert Pharmaceuticals Inc. Novel aryloxyphenylpropanamines
US20070116643A1 (en) 2005-07-01 2007-05-24 Concert Pharmaceuticals Inc. Novel aryloxypropanamines
CN101273024A (zh) 2005-07-29 2008-09-24 康瑟特制药公司 新颖苯并[d][1,3]-二氧杂环戊烯衍生物
JP2009502961A (ja) 2005-07-29 2009-01-29 コンサート ファーマシューティカルズ インコーポレイテッド 新規な医薬組成物
DK1983989T3 (da) * 2006-02-09 2013-10-14 Ca Nat Research Council Kombinationer af botaniske ekstrakter til fremme af kardiovaskulær sundhed
CN100509840C (zh) * 2006-05-10 2009-07-08 华中科技大学 浙贝乙素和胆汁酸的衍生物及药物组合物
CN101113149B (zh) * 2006-07-25 2011-04-27 复旦大学 小檗碱类生物碱的脂肪族有机酸盐及其制备方法和应用
CA2679309C (en) * 2007-02-28 2015-05-26 Denka Seiken Co., Ltd. Reagent for quantitative determination of small, dense ldls
JP5647519B2 (ja) * 2007-09-13 2014-12-24 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化カテコールおよびベンゾ［ｄ］［１，３］ジオキソールおよびその誘導体の合成
KR20110021828A (ko) * 2008-05-01 2011-03-04 아펙사 라이프 사이언시즈 인코퍼레이티드 혈중 지질 수준을 저하시키는데 효과적인 황련과 고정차의 추출물을 포함하는 제약 조성물
IT1393095B1 (it) * 2009-02-19 2012-04-11 Prodotti Chimici Alimentari Processo per la sintesi del sale disodico dell'acido ursodesossicolico 3,7-disolfato.
RU2011139643A (ru) * 2009-03-17 2013-04-27 Акскан Фарма, Инк. Способ лечения неалкогольного стеатогепатита повышенными дозами урсодезоксихолевой кислоты
JP2010246578A (ja) * 2009-04-10 2010-11-04 Utsunomiya Univ 血中コレステロールの検査方法および検査装置
US20100323031A1 (en) * 2009-06-22 2010-12-23 Glykon Technologies Group, Llc Synergistic combination to enhance blood glucose and insulin metabolism
CN101987860B (zh) * 2009-08-06 2011-12-14 中山百灵生物技术有限公司 一种熊去氧胆酸的制备方法
CN101879162A (zh) 2010-02-23 2010-11-10 江苏格林生物科技有限公司 一种α-亚麻酸乙酯配伍小檗碱的减肥物
CN102869382A (zh) * 2010-06-10 2013-01-09 (株)Ad生物技 通过抑制肠内胆固醇吸收而抑制高脂血症和肥胖症的组合物
CN101935319A (zh) * 2010-09-09 2011-01-05 陕西科技大学 一种黄连素有机酸盐和黄连素有机酸盐包合物及其制备方法
CN102078418B (zh) * 2011-01-14 2012-04-18 广东药学院 一种防治脂代谢紊乱的复方中药提取物及其制备方法
CN102225961A (zh) * 2011-04-21 2011-10-26 东北林业大学 小檗碱9位偶合胆酸新衍生物及其制备方法
CN102370643A (zh) 2011-07-20 2012-03-14 吉林敖东集团大连药业股份有限公司 盐酸小檗碱药物组合物及其制备方法
EP2766033B1 (en) * 2011-10-14 2019-11-20 Novartis AG Antibodies and methods for wnt pathway-related diseases
CN102580087B (zh) 2012-03-08 2013-08-21 董萍 一种可用于人体局部减肥和美体的原位脂肪细胞系复合抑制剂及其制备方法
CN103319479B (zh) * 2012-03-20 2015-08-26 王从品 大黄酸小檗碱离子对化合物、制备方法及应用
US8652518B2 (en) 2012-04-15 2014-02-18 Jahahreeh Finley Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation
CN102702190B (zh) * 2012-07-02 2016-04-27 东北制药集团股份有限公司 一种小檗碱静电复合物及其制备方法
CA2880929A1 (en) * 2012-09-07 2014-03-13 Sanofi Fusion proteins for treating a metabolic syndrome
CA2912302A1 (en) 2013-05-14 2014-11-20 University Of Prince Edward Island Compositions and methods for treating cardiometabolic diseases and disorders
CN103989677A (zh) * 2013-12-20 2014-08-20 中国药科大学 去亚甲基小檗碱在制备降血糖药物中的应用
US20150284406A1 (en) * 2014-04-04 2015-10-08 North American Biomedical Research Center Usa, Inc Berberine-ursodeoxycholic acid conjugate for treating the liver
WO2015183794A1 (en) * 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
CA3194562C (en) * 2014-07-29 2026-03-17 Shenzhen Hightide Biopharmaceutical, Ltd. Berberine-ursodeoxycholic salt, method of preparation and application therof

Also Published As

Publication number Publication date
CN106687460A (zh) 2017-05-17
AU2019222911A1 (en) 2019-09-19
NZ728488A (en) 2023-03-31
MX2022009595A (es) 2022-09-02
WO2016015634A1 (en) 2016-02-04
ES2835874T3 (es) 2021-06-23
CN110179792A (zh) 2019-08-30
EA032971B1 (ru) 2019-08-30
MX2017001372A (es) 2017-08-21
US10301303B2 (en) 2019-05-28
US11685735B2 (en) 2023-06-27
BR112017001623B1 (pt) 2022-11-29
MX373840B (es) 2020-03-25
IL294063A (en) 2022-08-01
CA2945609A1 (en) 2016-02-04
BR112017001623A2 (pt) 2017-11-21
US20230295151A1 (en) 2023-09-21
JP2022020854A (ja) 2022-02-01
KR102573865B1 (ko) 2023-09-05
AU2019222911B2 (en) 2021-05-20
IL282156B (en) 2022-07-01
JP6917144B2 (ja) 2021-08-11
US11976063B2 (en) 2024-05-07
AU2015296098A1 (en) 2016-11-03
CA2945609C (en) 2023-05-23
MX2019013426A (es) 2020-02-07
JP7285903B2 (ja) 2023-06-02
US10988471B2 (en) 2021-04-27
IL282156A (en) 2021-05-31
JP2020073546A (ja) 2020-05-14
EA201790124A1 (ru) 2017-07-31
IL294063B2 (en) 2024-12-01
CA3194562C (en) 2026-03-17
AU2015296098B2 (en) 2019-06-27
EP3174874A1 (en) 2017-06-07
KR20230019267A (ko) 2023-02-08
EP3174874B1 (en) 2020-09-02
CN106687460B (zh) 2019-05-17
IL250317B (en) 2021-04-29
DK3174874T3 (da) 2020-12-07
KR20230134598A (ko) 2023-09-21
IL250317A0 (en) 2017-03-30
IL294063B1 (en) 2024-08-01
JP2023099689A (ja) 2023-07-13
US20210300915A1 (en) 2021-09-30
JP2017522264A (ja) 2017-08-10
CA3194562A1 (en) 2016-02-04
CA3290585A1 (en) 2026-03-02
US20170037043A1 (en) 2017-02-09
KR20250008786A (ko) 2025-01-15
US20190211007A1 (en) 2019-07-11
EP3174874A4 (en) 2019-03-13

Similar Documents

Publication Publication Date Title
IL250317A0 (en) Salts of berberic acid, salts of ursodeoxycholic acid and their combinations, methods for their preparation and their uses
IL272306B (en) Pridopidine analogues, their preparation and use
PL3181560T3 (pl) Pochodna pirydynoamidopirymidyny, sposób jej otrzymywania i zastosowanie
IL264454A (en) Novel compositions, uses and methods for making them
EP3159424A4 (en) Rebar and preparation method thereof
PL4036094T3 (pl) Podstawione 4‑fenylopiperydyny, ich wytwarzanie i zastosowanie
IL253234B (en) Methods for transdifferentiation and methods to use them
IL248529B (en) Palladianolide pyridine compounds and methods of use
SG11201608372PA (en) Irinotecan hydrochloride composite phospholipid composition, preparation method and use thereof
IL268570B (en) Oligonucleotide compositions and methods of making the same
EP3093296A4 (en) Fuc3s4s substituted oligoglycosaminoglycan and preparation method thereof
PT3398598T (pt) Derivado de sulfonamida e método de preparação e utilização do mesmo
GB201416293D0 (en) Methods and preparations
ZA201704743B (en) Mangiferin-6-o-berberine salt and preparation method and use thereof
EP3130340A4 (en) Isoacteoside derivative and preparation method and use thereof
PT3327012T (pt) Formas cristalinas de bilastina e os seus métodos de preparação
IL253174A0 (en) Nanoparticles and methods for their preparation
IL254597A0 (en) Crystalline form of ahu377, method for its preparation and use
IL249073A0 (en) Cytin-glucan complex, its preparation and uses
EP3132790A4 (en) Exenatide-containing composition and preparation method therefor
ZA201605516B (en) Arrangement and method for deep soil preparation
GB201516107D0 (en) Complexes and methods for their preparation
EP3110459A4 (en) Biocidal composition, preparation and methods of use thereof
ZA201708339B (en) Primin derivatives, method of preparation thereof and use thereof
GB201404133D0 (en) Garment and method of use thereof